Drug Trial Radar · NCT00087490
Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
Last checked: Nov 20, 2026Latest source record: Aug 8, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,077
Actual
Start
Oct 2004
Primary completion
Jul 2007
Study completion Jul 2007
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jul 13, 2004
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine if linezolid is superior to vancomycin in the treatment of complicated skin and soft tissue infections due to MRSA in adult subjects
Conditions
- Skin/Soft Tissue Infections
- Methicillin Resistant Staphylococcus Aureus (MRSA)
Interventions
linezolidDrug
vancomycinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Outcome in Participants With Baseline Methicillin-Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for Per-Protocol (PP) PopulationTime frame: EOS (6 to 28 days after the last dose of study drug)
Locations
126 sites in 16 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Montgomery, Alabama
Pfizer Investigational Site
Tucson, Arizona
Pfizer Investigational Site
Los Angeles, California
Pfizer Investigational Site
Palm Springs, California
Pfizer Investigational Site
Rancho Mirage, California
Pfizer Investigational Site
San Pedro, California
Pfizer Investigational Site
Santa Fe Springs, California
Pfizer Investigational Site
Sylmar, California
Pfizer Investigational Site
Torrance, California
Pfizer Investigational Site
Torrance, California
Pfizer Investigational Site
Torrance, California
Pfizer Investigational Site
Denver, Colorado
Pfizer Investigational Site
Denver, Colorado
Pfizer Investigational Site
Hartford, Connecticut
Pfizer Investigational Site
Hartford, Connecticut
Pfizer Investigational Site
New Haven, Connecticut
Pfizer Investigational Site
New Haven, Connecticut
Pfizer Investigational Site
Atlantis, Florida
Pfizer Investigational Site
Melbourne, Florida
Pfizer Investigational Site
Miami, Florida
Pfizer Investigational Site
Pensacola, Florida
Pfizer Investigational Site
Atlanta, Georgia
Pfizer Investigational Site
Augusta, Georgia
Pfizer Investigational Site
Blue Ridge, Georgia
Pfizer Investigational Site
Honolulu, Hawaii
Pfizer Investigational Site
Honolulu, Hawaii
Pfizer Investigational Site
Chicago, Illinois
Pfizer Investigational Site
Decatur, Illinois
Pfizer Investigational Site
Hines, Illinois
Pfizer Investigational Site
Maywood, Illinois
Pfizer Investigational Site
North Chicago, Illinois
Pfizer Investigational Site
Northlake, Illinois
Pfizer Investigational Site
Springfield, Illinois
Pfizer Investigational Site
Springfield, Illinois
Pfizer Investigational Site
Iowa City, Iowa
Pfizer Investigational Site
Louisville, Kentucky
Pfizer Investigational Site
Louisville, Kentucky
Pfizer Investigational Site
Louisville, Kentucky
Pfizer Investigational Site
New Orleans, Louisiana
Pfizer Investigational Site
Baltimore, Maryland
Showing 40 of 126 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.